Paper36729264
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.
Wang Y and 1 other. Cancer Metastasis Rev, 2023. Cited by 386 papers, by iCite.
Cite this record
ConductScience Library. Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers. Papers, record 36729264. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36729264
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Oncogenes | |
| Biomarkers | |
| Signal Transduction | |
| Molecular Targeted Therapy | |
| Biomarkers, Tumor |
Source PubMed
References167
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33538338 | Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. | CA Cancer J Clin | 2021 | https://conductscience.org/library/papers/33538338 | PubMed |
| 2 | 30970190 | Hepatocellular Carcinoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30970190 | PubMed |
| 3 | 25832714 | The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications. | Eur J Clin Invest | 2015 | https://conductscience.org/library/papers/25832714 | PubMed |
| 4 | 26244070 | Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. | World J Hepatol | 2015 | https://conductscience.org/library/papers/26244070 | PubMed |
| 5 | 21829020 | Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. | Dig Dis | 2011 | https://conductscience.org/library/papers/21829020 | PubMed |
| 6 | 9288757 | hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. | Cell | 1997 | https://conductscience.org/library/papers/9288757 | PubMed |
| 7 | 24400224 | From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. | Liver Cancer | 2013 | https://conductscience.org/library/papers/24400224 | PubMed |
| 8 | 27602122 | Hepatitis B virus X protein mediates yes-associated protein 1 upregulation in hepatocellular carcinoma. | Oncol Lett | 2016 | https://conductscience.org/library/papers/27602122 | PubMed |
| 9 | 23504944 | Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. | Hepatology | 2013 | https://conductscience.org/library/papers/23504944 | PubMed |
| 10 | 32879846 | Novel molecular targets in hepatocellular carcinoma. | World J Clin Oncol | 2020 | https://conductscience.org/library/papers/32879846 | PubMed |
| 11 | 31954490 | Epidemiology and surveillance for hepatocellular carcinoma: New trends. | J Hepatol | 2020 | https://conductscience.org/library/papers/31954490 | PubMed |
| 12 | 32319693 | Epidemiology of Hepatocellular Carcinoma. | Hepatology | 2021 | https://conductscience.org/library/papers/32319693 | PubMed |
| 13 | 16729298 | The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. | Hepatology | 2006 | https://conductscience.org/library/papers/16729298 | PubMed |
| 14 | 29388206 | Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. | Int J Cancer | 2018 | https://conductscience.org/library/papers/29388206 | PubMed |
| 15 | 32151618 | Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. | J Hepatol | 2020 | https://conductscience.org/library/papers/32151618 | PubMed |
| 16 | 27746337 | Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. | J Hepatol | 2017 | https://conductscience.org/library/papers/27746337 | PubMed |
| 17 | 8707279 | Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. | Hepatology | 1996 | https://conductscience.org/library/papers/8707279 | PubMed |
| 18 | 28509392 | Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. | Int J Cancer | 2017 | https://conductscience.org/library/papers/28509392 | PubMed |
| 19 | 31119044 | Qidong: a crucible for studies on liver cancer etiology and prevention. | Cancer Biol Med | 2019 | https://conductscience.org/library/papers/31119044 | PubMed |
| 20 | 8580413 | Primary prevention of hepatocellular carcinoma. | J Gastroenterol Hepatol | 1995 | https://conductscience.org/library/papers/8580413 | PubMed |
Cited by306
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 386 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42964600 | An efficient hypochlorous acid fluorescence imaging strategy based on toehold-mediated strand displacement for distinguishing cancer cells from normal cells. | RSC Adv | 2026 | https://conductscience.org/library/papers/42964600 | PubMed |
| 42963792 | Critical roles of the long noncoding RNA SNHG4 in human cancers. | Cell Div | 2026 | https://conductscience.org/library/papers/42963792 | PubMed |
| 42952736 | Survival benefits and prognostic models of surgical resection versus continued medical treatment in CNLC stage IIb/IIIa hepatocellular carcinoma after meeting resectability criteria following conversion therapy. | Front Oncol | 2026 | https://conductscience.org/library/papers/42952736 | PubMed |
| 42878001 | ATF6-mediated GTPase RHOQ promotes liver cancer progression via enhancing aerobic glycolysis through PAK1 phosphorylation. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42878001 | PubMed |
| 42847779 | Deconformer: efficient cell-type composition profiling of cfRNA across diverse cell types. | Brief Bioinform | 2026 | https://conductscience.org/library/papers/42847779 | PubMed |
| 42801010 | miR-139-5p Targets CENPM to Suppress EMT and Malignant Progression of Hepatocellular Carcinoma via Regulating the Akt/mTOR Pathway and β-Catenin Nuclear Translocation. | J Hepatocell Carcinoma | 2026 | https://conductscience.org/library/papers/42801010 | PubMed |
| 42794416 | ADCK1 Regulates Mitochondrial Bioenergetics in Hepatocellular Carcinoma In Vitro. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42794416 | PubMed |
| 42792641 | Rewiring of Molecular Networks Induced by the Combination of Loratadine, Raloxifene, and Sorafenib Leads to the Identification of Clinically Relevant Therapeutic Targets in Hepatocellular Carcinoma. | Biomedicines | 2026 | https://conductscience.org/library/papers/42792641 | PubMed |
| 42760533 | ZMIZ1 promotes aerobic glycolysis and development of hepatocellular carcinoma through inducing NOTCH1-mediated transcription of PYCR1. | J Transl Med | 2026 | https://conductscience.org/library/papers/42760533 | PubMed |
| 42747623 | Amino acid transporters in hepatocellular carcinoma: Gatekeepers of metabolic reprogramming. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42747623 | PubMed |
| 42737438 | Integrated Transcriptomic Analyses Identify Four Prognosis-Associated Genes in Hepatocellular Carcinoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737438 | PubMed |
| 42729464 | Neutrophil Senescence Induced by Tumor-Derived HMGB1 Promotes Hepatocellular Carcinoma Progression through Neutrophil Extracellular Trap-Mediated Suppression of CD8+ T Cell Immunity. | Cancer Commun (Lond) | 2026 | https://conductscience.org/library/papers/42729464 | PubMed |
| 42724514 | Akkermansia muciniphila attenuates apatinib resistance in hepatocellular carcinoma through NF-κB-mediated reprogramming of tumor-associated macrophages. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724514 | PubMed |
| 42683851 | Synergistic effects of sorafenib and cilostazol in HepG2 cells. | J Biosci | 2026 | https://conductscience.org/library/papers/42683851 | PubMed |
| 42639779 | Effect of Jinlong capsule on the survival of patients with hepatocellular carcinoma: a propensity score matching study. | J Tradit Chin Med | 2026 | https://conductscience.org/library/papers/42639779 | PubMed |
| 42604028 | Aptamer-based nanoparticle drug delivery system designed for targeting GPC3-positive liver cancer. | J Pharm Anal | 2026 | https://conductscience.org/library/papers/42604028 | PubMed |
| 42593582 | DBF4B promotes hepatocellular carcinoma progression by regulating CCNA2 and PSMD11 expression. | Mol Biol Rep | 2026 | https://conductscience.org/library/papers/42593582 | PubMed |
| 42566146 | METTL3 promotes proliferation and invasion and inhibits ferroptosis in hepatocellular carcinoma by mediating m6A methylation modification of NUPR1. | Mol Cell Biochem | 2026 | https://conductscience.org/library/papers/42566146 | PubMed |
| 42506898 | ATP7A Orchestrates Tumor Progression and Cuproptosis in Hepatocellular Carcinoma via the LINC02038-miR-506-3p Regulatory Circuit. | J Biochem Mol Toxicol | 2026 | https://conductscience.org/library/papers/42506898 | PubMed |
| 42483739 | Targeting the 4EBP1/HSP90β/Nrf2 Axis Sensitizes β-catenin-mutant Hepatocellular Carcinoma to mTOR Inhibitors via Ferroptosis Induction. | J Clin Transl Hepatol | 2026 | https://conductscience.org/library/papers/42483739 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36729264
GET https://conductscience.org/api/papers/v1/36729264/references?page=2